0QT6.IL - Genfit S.A.
| Previous close | 3.9125 |
| Open | 0.0000 |
| Bid | 3.7800 x 0 |
| Ask | 3.9700 x 0 |
| Day's range | 3.8850 - 3.8850 |
| 52-week range | 3.0140 - 4.7280 |
| Volume | |
| Avg. volume | 10,485 |
| Market cap | 193.609M |
| Beta (5Y monthly) | 0.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4900 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
GENFIT Announces New Data at the European Association for the Study of the Liver (EASL) Congress 2023
Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); June 7, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced that it will present new data at the EASL Congress which will take place on June 21-24, 2023 in Vienna, Austria. Posters and Presentations GENFIT has had three abstracts accepted for poster sessions. Presentations include preclinica
- Globe Newswire
GENFIT Further Strengthens its ACLF Franchise with a Third Clinical-Stage Asset
Exclusive worldwide rights licensed from Seal Rock Therapeutics for injectable formulation of ASK1 Inhibitor SRT-015 in acute liver diseasePreclinical and clinical evidence support ASK1 inhibition as a relevant therapeutic strategy in multi-system disorders such as Acute-on-Chronic Liver Failure (ACLF)First-in-Human study planned in the second half of 2024 to support a Proof-of-Concept study in ACLF patients as early as 2025No material impact on previously guided cash runway: company funding rem
- Globe Newswire
GENFIT: May 24, 2023 Combined Shareholders Meeting results
Quorum of 29.54% on first convening; allowing approval of all the resolutions recommended by the Board of Directors Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); May 24, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced the results of the Combined Shareholders Meeting which took place on May 24, 2023. The quorum on first convening amo
- Globe Newswire
GENFIT Announces Publication of the Development and Validation of NIS2+™ in the Journal of Hepatology
Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); May 23, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced the publication of the development and validation of NIS2+™ in the Journal of Hepatology.1 NIS2+™ is a next-generation technology for the diagnosis of at-risk Non-Alcoholic Steatohepatitis (NASH). It is a non-invasive diagnostic tec
- Globe Newswire
GENFIT Reports First Quarter 2023 Financial Information
Cash, cash equivalents and current financial assets totaled €128.6 million as of March 31, 2023 Lille (France); Cambridge, (Massachusetts, United States); Zurich (Switzerland); May 11, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced its cash position as of March 31, 2023 and revenues for the first three months of 20231. Cash Position As of March 31, 2023, the Compan
- Globe Newswire
GENFIT Presents Phase 1 Clinical Data Evaluating NTZ at Digestive Disease Week® as part of its ACLF Program
Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); May 9, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced that it is presenting Phase 1 clinical data evaluating NTZ as part of its Acute-on-Chronic Liver Failure (ACLF) Program at Digestive Disease Week®, taking place from May 6-9, 2023 in Chicago, Illinois (USA). The Phase 1, open-label c
- Globe Newswire
GENFIT Announces Publication of Extra-Financial Performance Report 2022
GENFIT Announces Publication of Extra-Financial Performance Report 2022 Lille (France); Cambridge, (Massachusetts, United States); Zurich (Switzerland); April 27, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced the publication of its Extra-Financial Performance Report 2022. GENFIT’s Extra-Financial Performance Report in its second edition Since 2022, GENFIT has been
- Globe Newswire
GENFIT Annual Combined General Meeting of May 24, 2023 — Availability of Preparatory Documents
Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); April 19, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced that it published in the April 19, 2023 French legal announcements bulletin n°47 (Bulletin des Annonces Légales Obligatoires) its convening notice that the Combined Shareholders Meeting will be held on May 24, 2023, at 10:00am (CET
- Globe Newswire
GENFIT Announces Publication of the 2022 Universal Registration Document and the 2022 Annual Report on Form 20-F
Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); April 18, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced the filing of its 2022 Universal Registration Document with the Autorité des marchés financiers (AMF) and its Annual Report on Form 20-F for the year ended December 31, 2022 with the U.S. Securities and Exchange Commission (SEC). T
- Globe Newswire
GENFIT Reports Full-Year 2022 Financial Results and Provides Corporate Update
Cash, cash equivalents and current financial assets totaled €140.2 million1 as of December 31, 2022, expected to fund operations through third quarter 2024Transformative milestone expected towards end of second quarter 2023, with topline data readout for Phase 3 ELATIVE® evaluating elafibranor in primary biliary cholangitis (PBC) Multiple events in second quarter 2023: 1st patient screening in a Phase 2 study evaluating VS-01 in acute on-chronic liver failure (ACLF)1st patient screening in a Pha
- Globe Newswire
GENFIT Announces Revenues and Cash Position as of December 31, 2022
Cash, cash equivalents and current financial instruments totaled €140.2 million as of December 31, 2022. Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); February 28, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, today announced its cash position as of December 31, 2022 and revenues for 2022. 1 2 Financials As of December 3
Globe NewswireGENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 30, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial. Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the
- Globe Newswire
GENFIT Announces 2023 Financial Calendar
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 24, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, today announced its provisional financial calendar for 2023. 2023 Financial Calendar February 28, 2023 Publication of revenue and cash position at December 31, 2022 April 13, 2023 Publication of Full Year 2022 financial
- Globe Newswire
GENFIT to Participate in Upcoming Investor Conferences
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 5, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, today announced that management will participate in upcoming investor conferences. Conference Details (non-exhaustive list): Corporate Access Events during the 41st JPMorgan Healthcare ConferenceDate: January 8 – 12, 202
- Globe Newswire
GENFIT Pipeline Day Highlights Diverse Product Portfolio in Underserved Liver Diseases
Phase 3 data for elafibranor in primary biliary cholangitis (PBC) expected in 2Q23Expanded pipeline now covers five therapeutic areas with high unmet medical need via six independent programs exploring the potential of differentiated mechanisms of actionA regular stream of new clinical data expected over the next few years across the spectrum of development stages (Phase 1, Phase 2, Phase 3)Aggregated global market size potential >$15bn1, distributed among acute on-chronic liver failure (ACLF) w
- Globe Newswire
GENFIT Reports Third Quarter 2022 Financial Information
Cash and cash equivalents: €163.6 million as of September 30, 2022 Lille, France; Cambridge, MA; November 10, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced its cash position as of September 30, 2022 and revenue for the first nine months of 20221. Cash Position As of September 30, 2022, the Company’s cash and cash equivalents amounted to €163.6 million compared with
- Globe Newswire
GENFIT Announces Compelling Results for Next-Generation Non-Invasive Diagnostic Technology NIS2+™ in NASH to be Presented at the AASLD Liver Meeting®
NIS2+™ developed and validated as an optimization of NIS4® technology for the detection of patients with at-risk NASHData demonstrate robust and improved clinical performance of NIS2+™ allowing an efficient identification of at-risk NASH, irrespective of patient characteristics such as age, sex and Type-2 diabetesNIS2+™’s analytical improvement allows for larger scale implementation in clinical practice and clinical trialsThree posters to be presented at AASLD Liver Meeting® Lille (France), Camb
- Globe Newswire
GENFIT Announces Signature of the Share Purchase Agreement and the Completion of its Acquisition of Versantis
Lille (France), Cambridge (Massachusetts, United States), September 29, 2022 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced the signing of the Share Purchase Agreement and the completion of its acquisition of Versantis AG (“Versantis”) under the terms announced in its press release on September 19, 2022. As a result of this acquisition, GENFIT consolidates its position i
- Globe Newswire
GENFIT Reports First Half-Year 2022 Financial Results and Provides Corporate Update
Financial highlights Cash and cash equivalents totaled €209 million as of June 30, 2022Net loss totaled €10 million for the first half 2022 Developments in our programs Patient enrollment for the double-blind part of the Phase 3 study in Primary Biliary Cholangitis (PBC) ELATIVETM completed at the end of the first semester 2022Orphan Drug Designation granted to GNS561 for the treatment of cholangiocarcinoma Agreement signed to acquire clinical-stage biotechnology company Versantis, further conso
- Globe Newswire
GENFIT to Acquire Clinical-stage Biopharmaceutical Company Versantis, expanding its Portfolio in Liver Diseases
Further consolidates GENFIT’s position as a leader in acute-on-chronic liver failure (ACLF)Significantly expands GENFIT’s pipeline with VS-01-ACLF, a Phase 2 ready program based on first-in-class scavenging liposomes technology, VS-01-UCD, a pediatric program focused on urea cycle disorder (UCD), and VS-02-HE, an early-stage program focused on hepatic encephalopathy (HE)Combines Versantis’ expertise with GENFIT’s know-how in conducting complex development programs in liver diseases, to strengthe
- Globe Newswire
FDA Grants GENFIT’s GNS561 Orphan Drug Designation for the Treatment of Cholangiocarcinoma
Lille (France), Cambridge (Massachusetts, United States), September 13, 2022 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to GNS5611 (ezurpimtrostat), a novel clinical-stage autophagy/PPT1 inhibitor, for the treatment of cholangiocarcinoma. Cholangiocarcinoma is a rare liver malignancy